PEspeaks

Nov 07, 2017
Despite FDA approval of seven biosimilars through October 2017, only three have come to market, fueling concerns about the safety of switching patients to new therapies.
Nov 07, 2017
Medical use of marijuana for a broad range of conditions is expanding rapidly in the US, but the future for this market is still uncertain, writes Harriet Kozak.
Nov 06, 2017
Pharmaceutical Executive
Can health stakeholders be friends without being captives? Reflector reports.
Nov 06, 2017
From Applied Clinical Trials
Experts are proposing more limited clinical trials for follow-on therapies in some situations, particularly for critical oncology drugs and for highly targeted treatments for rare conditions. Jill Wechsler reports.
Oct 24, 2017
Pharmaceutical Executive
Brenda Gleason discusses the current health policy landscape and how future pharmacists can be healthcare leaders during a lecture at University of North Carolina Eshelman School of Pharmacy.
Oct 18, 2017
The status quo pharma marketing model is still relied upon by the big brands, not because the results are amazing, but because they are predictable. It's time to challenge convention, says James Talerico.
Oct 12, 2017
Most physicians and many specialists have limited understanding of clinical trial data and research findings presented in prescription drug promotional materials for professional audiences.
Oct 12, 2017
Bhaskar Sambasivan offers a prescription for thriving in the new digital economy.
Oct 11, 2017
Pharmaceutical Executive
FDA seeks to de-risk research and promote competition to achieve savings for patients and plans.
Oct 10, 2017
FDA is evaluating whether limiting warnings in TV commercials to the most serious adverse effects might be more informative for consumers than the current laundry lists of potential side effects.
native1_300x100
lorem ipsum